Skip to main navigation Skip to search Skip to main content

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  • ATLANTIC Investigators

    Research output: Contribution to journal › Article › peer-review

    550   Link opens in a new tab Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study'. Together they form a unique fingerprint.
    Sort by

    Keyphrases

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Biochemistry, Genetics and Molecular Biology